ALC-0159
| |
| Names | |
|---|---|
| Other names
2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide
| |
| Identifiers | |
| UNII | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
ALC-0159 is a PEG/lipid conjugate (i.e. PEGylated lipid), specifically, it is the N,N-dimyristylamide of 2-hydroxyacetic acid, O-pegylated to a PEG chain mass of about 2 kilodaltons (corresponding to about 45-46 ethylene oxide units per molecule of N,N-dimyristyl hydroxyacetamide). It is a non-ionic surfactant by its nature. It has been deployed in the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine (0.05 mg per dose)[1] that contains the active ingredient tozinameran.[2]
See also
- Pfizer–BioNTech COVID-19 vaccine nanoparticle ingredients
- Others
References
- ^ Schoenmaker, Linde; Witzigmann, Dominik; Kulkarni, Jayesh A.; Verbeke, Rein; Kersten, Gideon; Jiskoot, Wim; Crommelin, Daan J. A. (2021-05-15). "mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability". International Journal of Pharmaceutics. 601: 120586. doi:10.1016/j.ijpharm.2021.120586. ISSN 0378-5173. PMC 8032477. PMID 33839230.
- ^ "Public Assessment Report Authorisation for Temporary Supply COVID-19 mRNA Vaccine BNT162b2 (BNT162b2 RNA) concentrate for solution for injection" (PDF). Regulation 174. MHRA. 15 December 2020.
- Assessment report, Comirnaty, Common name: COVID-19 mRNA vaccine (nucleoside-modified); Procedure No. EMEA/H/C/005735/0000 - gives structural formula for the compound (p. 24)
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |